LNTH Lantheus Holdings Inc

Lantheus Holdings Announces Presentation Featuring 18F-DCFPyL PET/CT, its PSMA-Targeted Prostate Cancer Imaging Agent at the 2021 ASCO Annual Meeting

Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to find, fight and follow serious medical conditions, announced today a poster presentation featuring data from the Company’s Phase 3 CONDOR study at the upcoming 2021 American Society for Clinical Oncology (ASCO) Virtual Meeting, which will be held from June 4-8, 2021.

The presentation will be made available for the duration of conference.

Details for the ASCO presentation are as follows:

Session Title: Poster Session: Genitourinary Cancer – Prostate, Testicular and Penile

Title: PSMA-targeted imaging with 18F-DCFPyL-PET/CT in patients (pts) with biochemically recurrent prostate cancer (PCa): A phase 3 study (CONDOR)—A subanalysis of correct localization rate (CLR) and positive predictive value (PPV) by standard of truth.

Presenter: Frederic Pouliot, M.D., Ph.D., F.R.C.S.C., Centre Hospitalier Universitaire (CHU) de Québec-Université Laval

Abstract No: 5023

About Lantheus Holdings, Inc.

Lantheus Holdings, Inc. is the parent company of Lantheus Medical Imaging, Inc., Progenics Pharmaceuticals, Inc. and EXINI Diagnostics AB and an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to Find Fight and Follow® serious medical conditions. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; TechneLite® (Technetium Tc99m Generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures; AZEDRA® for the treatment of certain rare neuroendocrine tumors; and RELISTOR® for the treatment of opioid-induced constipation, which is partnered with Bausch Health Companies, Inc. The Company is headquartered in North Billerica, Massachusetts with offices in New York, New Jersey, Canada and Sweden. For more information, please visit .

EN
21/05/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Lantheus Holdings Inc

 PRESS RELEASE

Lantheus to Present at the Leerink Partners Global Biopharma Conferenc...

Lantheus to Present at the Leerink Partners Global Biopharma Conference 2024 BEDFORD, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced Paul Blanchfield, President, will present at the Leerink Partners Global Biopharma Conference 2024 at 9:20 a.m. ET on Tuesday, March 12. To access a live webcast of the presentation, please visit the  section of the Company’s website at . A repla...

 PRESS RELEASE

Lantheus Announces the FDA Approval of DEFINITY® (Perflutren Lipid Mic...

Lantheus Announces the FDA Approval of DEFINITY® (Perflutren Lipid Microsphere) for Pediatric Patients DEFINITY is the #1 utilized ultrasound enhancing agent in the U.S. for patients with suboptimal echocardiograms BEDFORD, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow® disease to deliver better patient outcomes, today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA)...

 PRESS RELEASE

Lantheus Announces Promotion of Amanda Morgan to Chief Commercial Offi...

Lantheus Announces Promotion of Amanda Morgan to Chief Commercial Officer BEDFORD, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced the promotion of Amanda Morgan to Chief Commercial Officer and her elevation to be a member of the company’s Executive Team, effective March 25, 2024. In her role, Ms. Morgan will continue to lead the Company’s commercial strategy and activities, incl...

 PRESS RELEASE

Lantheus to Present at the TD Cowen 44th Annual Health Care Conference

Lantheus to Present at the TD Cowen 44th Annual Health Care Conference BEDFORD, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced Paul Blanchfield, President, will present at the TD Cowen 44th Annual Health Care Conference at 10:30 a.m. ET on Monday, March 4. To access a live webcast of the presentation, please visit the  section of the Company’s website at . A replay of the webca...

 PRESS RELEASE

Lantheus Reports Fourth Quarter and Full Year 2023 Financial Results

Lantheus Reports Fourth Quarter and Full Year 2023 Financial Results Worldwide revenue of $354.0 million and $1.3 billion for the fourth quarter and full year 2023GAAP net income of $103.4 million and $326.7 million for the fourth quarter and full year 2023GAAP fully diluted net income per share of $1.47 and $4.65 for the fourth quarter and full year 2023 Adjusted fully diluted net income per share of $1.75 and $6.23 for the fourth quarter and full year 2023Net cash provided by operating activities was $112.3 million and $305.3 million for the fourth quarter and full year 2023 and free cash...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch